Pruritus
154
11
11
105
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
33 trials with published results (21%)
Research Maturity
105 completed trials (68% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
8.4%
13 terminated out of 154 trials
89.0%
+2.4% vs benchmark
19%
30 trials in Phase 3/4
31%
33 of 105 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 105 completed trials
Clinical Trials (154)
Drug-induced Liver Injury: Itching Study
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Establishment of a Patient Library in Patients With Pruritus Sine Materia
Efficacy and Tolerance of THC 25: CBD 25 in Patients With Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study
Health Belief Model-Based Education for Pruritus and Quality of Life in Hemodialysis Patients
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Methotrexate Versus Apremilast for Pruritus in Psoriasis
Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque Psoriasis, Dry Skin and Pruritus
Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus
Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans
VR-PMR for Post-Burn Symptoms
Non Interventional Clinical Investigation of Ectoin Ear Spray in Skin Treatment of Outer Ear Canal Irritations
Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Effect of Topically Applied Olive Oil on Pruritus in Hemodialysis Patients: Pretest-posttest Model With Control Group
TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis
Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis